VAXART INC (VXRT)
US92243A2006 - Common Stock
VXRT gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 564 industry peers in the Biotechnology industry. Both the profitability and financial health of VXRT have multiple concerns. VXRT is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year VXRT has reported negative net income.
In the past year VXRT has reported a negative cash flow from operations.
In the past 5 years VXRT always reported negative net income.
VXRT had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
VXRT has a Return On Assets (-43.40%) which is in line with its industry peers.
VXRT's Return On Equity of -105.69% is in line compared to the rest of the industry. VXRT outperforms 44.70% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -43.4% | ||
| ROE | -105.69% | ||
| ROIC | N/A |
ROA(3y)-63.92%
ROA(5y)-52.63%
ROE(3y)-92.58%
ROE(5y)-89.38%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
VXRT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
VXRT does not have a ROIC to compare to the WACC, probably because it is not profitable.
VXRT has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, VXRT has more shares outstanding
Compared to 1 year ago, VXRT has a worse debt to assets ratio.
2.2 Solvency
VXRT has an Altman-Z score of -4.16. This is a bad value and indicates that VXRT is not financially healthy and even has some risk of bankruptcy.
VXRT has a Altman-Z score (-4.16) which is in line with its industry peers.
VXRT has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
VXRT's Debt to Equity ratio of 0.03 is in line compared to the rest of the industry. VXRT outperforms 41.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.16 |
ROIC/WACCN/A
WACC10.55%
2.3 Liquidity
A Current Ratio of 0.83 indicates that VXRT may have some problems paying its short term obligations.
VXRT's Current ratio of 0.83 is on the low side compared to the rest of the industry. VXRT is outperformed by 90.13% of its industry peers.
A Quick Ratio of 0.83 indicates that VXRT may have some problems paying its short term obligations.
With a Quick ratio value of 0.83, VXRT is not doing good in the industry: 89.41% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.83 | ||
| Quick Ratio | 0.83 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 35.94% over the past year.
The Revenue has grown by 302.88% in the past year. This is a very strong growth!
VXRT shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.93% yearly.
EPS 1Y (TTM)35.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.45%
Revenue 1Y (TTM)302.88%
Revenue growth 3Y22.64%
Revenue growth 5Y11.93%
Sales Q2Q%134.79%
3.2 Future
VXRT is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 3.71% yearly.
Based on estimates for the next years, VXRT will show a very strong growth in Revenue. The Revenue will grow by 114.10% on average per year.
EPS Next Y32%
EPS Next 2Y15.32%
EPS Next 3Y7.54%
EPS Next 5Y3.71%
Revenue Next Year433.08%
Revenue Next 2Y91.35%
Revenue Next 3Y75.58%
Revenue Next 5Y114.1%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for VXRT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VXRT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.32%
EPS Next 3Y7.54%
5. Dividend
5.1 Amount
VXRT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
VAXART INC
NASDAQ:VXRT (1/3/2025, 8:09:54 PM)
After market: 0.839 +0 (+0.19%)0.8374
+0.12 (+16.52%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners18.17%
Inst Owner Change-9.36%
Ins Owners0.87%
Ins Owner Change-0.2%
Market Cap190.49M
Analysts86.67
Price Target4.93 (488.73%)
Short Float %5.01%
Short Ratio7.18
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-94.83%
Min EPS beat(2)-230.84%
Max EPS beat(2)41.18%
EPS beat(4)3
Avg EPS beat(4)-42.21%
Min EPS beat(4)-230.84%
Max EPS beat(4)41.18%
EPS beat(8)7
Avg EPS beat(8)-11.8%
EPS beat(12)9
Avg EPS beat(12)-9.45%
EPS beat(16)11
Avg EPS beat(16)-12.06%
Revenue beat(2)2
Avg Revenue beat(2)3322.23%
Min Revenue beat(2)468.97%
Max Revenue beat(2)6175.49%
Revenue beat(4)4
Avg Revenue beat(4)1741.56%
Min Revenue beat(4)154.51%
Max Revenue beat(4)6175.49%
Revenue beat(8)6
Avg Revenue beat(8)1288.67%
Revenue beat(12)6
Avg Revenue beat(12)835.1%
Revenue beat(16)6
Avg Revenue beat(16)612.97%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-29.55%
EPS NY rev (1m)10.77%
EPS NY rev (3m)18.31%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)66.69%
Revenue NY rev (1m)13.19%
Revenue NY rev (3m)36.23%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 11.37 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.78 | ||
| P/tB | 3.16 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.41
EYN/A
EPS(NY)-0.39
Fwd EYN/A
FCF(TTM)-0.23
FCFYN/A
OCF(TTM)-0.22
OCFYN/A
SpS0.07
BVpS0.3
TBVpS0.26
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -43.4% | ||
| ROE | -105.69% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-63.92%
ROA(5y)-52.63%
ROE(3y)-92.58%
ROE(5y)-89.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.1
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 4.48% | ||
| Cap/Sales | 2.39% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.83 | ||
| Quick Ratio | 0.83 | ||
| Altman-Z | -4.16 |
F-Score5
WACC10.55%
ROIC/WACCN/A
Cap/Depr(3y)103.16%
Cap/Depr(5y)75.62%
Cap/Sales(3y)3399.56%
Cap/Sales(5y)2047.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)35.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.45%
EPS Next Y32%
EPS Next 2Y15.32%
EPS Next 3Y7.54%
EPS Next 5Y3.71%
Revenue 1Y (TTM)302.88%
Revenue growth 3Y22.64%
Revenue growth 5Y11.93%
Sales Q2Q%134.79%
Revenue Next Year433.08%
Revenue Next 2Y91.35%
Revenue Next 3Y75.58%
Revenue Next 5Y114.1%
EBIT growth 1Y23.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y44.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y37.45%
OCF growth 3YN/A
OCF growth 5YN/A